Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

891518

registered interest
date	25/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Spinal Injuries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 23 April 2018 to Question 136434 on spinal injuries, what steps his Department is taking to submit the fully costed breakdown of the £855 million in efficiency savings from the NHS Continuing Health Care budget as recommended in paragraph 5 of the 13th Report of the Public Accounts Committee, NHS Continuing Healthcare Funding, HC 455, published on 17 January 2018.
tabling member constituency	Westmorland and Lonsdale
tabling member printed	Tim Farron
uin	138017
answer	answer is ministerial correction date of answer 30/04/2018 answer text <p>The Government published its response to the Public Accounts Committee January 2018 report and recommendations on NHS Continuing Healthcare Funding in March 2018.</p><p> </p><p>Continuing Healthcare expenditure (after efficiencies) is forecast to increase over the period to 2020/21, and the identified efficiency opportunity is not predicated on changes to the National Framework in respect of eligibility or on limiting the care packages available.</p><p> </p><p>How any efficiency is delivered in practice will be determined by clinical commissioning groups (CCGs) locally, consistent with their statutory duties and national guidance in respect of access to Continuing Healthcare. National modelling based on variations in Continuing Healthcare expenditure and practice suggests the following notional efficiency opportunities in 2020/21, amounting to circa £855 million, which it is anticipated will inform local commissioning decisions:</p><p> </p><p>- NHS England working with the Department to provide clarity around the National Framework and improving the way CCGs deliver the National Framework. This includes interventions such as improved data and benchmarking information and reducing the number of Continuing Healthcare assessments in an acute hospital setting – (circa £361 million);</p><p>- Improving the commissioning of care packages – (circa £122 million);</p><p>- Improving Continuing Healthcare processes including the supporting of staff with training and development – (circa £79 million); and</p><p>- CCGs locally delivered improvement initiatives – (circa £293 million).</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 30/04/2018 15:38:07 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	1591 label Biography information for Tim Farron

891519

registered interest
date	25/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Continuing Care
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of external agencies running care packages for those receiving NHS Continuing Health Care on a) the standard of care provided and (b) the consideration of the patient's needs.
tabling member constituency	Westmorland and Lonsdale
tabling member printed	Tim Farron
uin	138018
answer	answer is ministerial correction date of answer 30/04/2018 answer text <p>Clinical commissioning groups (CCGs) are the organisation responsible for commissioning care, based on an individual’s assessed needs and providing assurance at a local level that the quality of care meets those needs. Furthermore the Care Quality Commission also has a responsibility for setting the standards for registration and taking appropriate actions if standards are not maintained.</p><p> </p><p>NHS England has a responsibility to assure compliance with the National Framework for NHS Continuing Healthcare, and have assurance mechanisms in place. NHS Continuing Health Care has been part of mainstream assurance processes since 2016/17 by being included in the CCG Improvement and Assessment Framework. NHS England local teams use an assurance tool, Continuing Healthcare Assurance Tool, to assess CCGs’ compliance with the NHS England Operating Model for NHS Continuing Healthcare.</p><p> </p><p>NHS England is working closely with the CCGs to ensure standardisation of the Continuing Healthcare processes which includes the development of tools to support effective commissioning.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 30/04/2018 15:35:33 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	1591 label Biography information for Tim Farron

891525

registered interest
date	25/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Department of Health and Social Care: Sick Leave
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of his Department's staff have had days off sick because of mental illness or stress in each of the last three years; and how many days off that amounted to in each of those years.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	138036
answer	answer is ministerial correction date of answer 30/04/2018 answer text <p>Departmental information systems do not record sickness absence relating to stress as a distinct category. Within the broader category that includes all mental health issues, the following table shows how many and the proportion of staff who have had days off sick and the total working days lost within that category in each of the last three years.</p><p> </p><table><tbody><tr><td><p>Category</p></td><td><p>2015</p></td><td><p>2016</p></td><td><p>2017</p></td></tr><tr><td><p>Number of staff members who had days off sick due to mental illness</p></td><td><p>88</p></td><td><p>82</p></td><td><p>44</p></td></tr><tr><td><p>Proportion of staff who had days off due to mental illness</p></td><td><p>4%</p></td><td><p>4%</p></td><td><p>2%</p></td></tr><tr><td><p>Total days lost due to mental illness</p></td><td><p>2,194</p></td><td><p>1,852</p></td><td><p>1,832</p></td></tr></tbody></table><p> </p><p>Note:</p><p>Data as at 31 December for each year.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 30/04/2018 15:40:06 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4036 label Biography information for Luciana Berger

891534

registered interest
date	25/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hereditary Diseases
house id	1
legislature	25259 pref label House of Commons
question text	to ask the Secretary of State for Health and Social Care, what lessons have been learned from the 100,000 Genome Project which will help when deciding what genetic diseases should be screened for at birth.
tabling member constituency	Bristol North West
tabling member printed	Darren Jones
uin	138095
answer	answer is ministerial correction date of answer 30/04/2018 answer text <p>The 100,000 Genomes Project is focussed on recruiting patients, including children, with rare diseases (and their family members) and those with common cancers. These are areas where whole genome sequencing may offer the best opportunity to diagnose disease. From the Project’s pilot phase we have found actionable findings in 20-25% of rare disease patients.</p><p> </p><p>The scope of the project does not include screening at birth. The Chief Medical Officer, in her annual report Generation Genome, recommended that that the National Screening Committee conducts a systematic evaluation of the opportunities offered by genomics for present and potential screening practices.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 30/04/2018 15:41:08 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4621 label Biography information for Darren Jones

885293

registered interest
date	23/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Visual Impairment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many people were registered blind in each of the last five years.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	136158
answer	answer is ministerial correction date of answer 24/04/2018 answer text <p>As NHS Digital collects data on a triennial basis, data can only be provided for two of the last five years.</p><p> </p><p>The number of people who were registered as blind or severely sight impaired in 2013/14 and 2016/17, as well as the number of people who were newly registered in those years is shown in the table below.</p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>Number of people registered blind or severely sight impaired*</p></td><td><p>Number of new registrations*</p></td></tr><tr><td><p>2013/14</p></td><td><p>143,385</p></td><td><p>8,875</p></td></tr><tr><td><p>2016/17</p></td><td><p>141,525</p></td><td><p>8,605</p></td></tr></tbody></table><p>Source: NHS Digital - The Registered Blind and Partially Sighted People collection (SSDA902).</p><p> </p><p>Notes:</p><p> </p><p>Data is also collected on registrations from those who are partially sighted/sight impaired. The figures in the table relate only to those registered blind or severely sight impaired.</p><p> </p><p>*Data is rounded to the nearest five.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 24/04/2018 14:10:37 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4131 label Biography information for Jim Shannon

890094

registered interest
date	23/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Department of Health and Social Care: Local Government
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many meetings he has had with representatives of local authorities since 1 January 2018.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	137144
answer	answer is ministerial correction date of answer 26/04/2018 answer text <p>The Secretary of State regularly meets a wide range of stakeholders to discuss a number of issues.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 26/04/2018 11:22:26 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	1506 label Biography information for Andrew Gwynne

890118

registered interest
date	23/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to maintain competition in clinical trials after the UK leaves the EU.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	137168
answer	answer is ministerial correction date of answer 26/04/2018 answer text <p>The Government has made clear that a key priority through the negotiations will be to ensure that the United Kingdom remains one of the best places in the world for science and innovation, including clinical trials. Every Government department, including the Department of Health and Social Care, is planning to deliver a smooth exit under any scenario, which includes preparing the UK for the future economic partnership we hope to negotiate with the European Union, as well as the very unlikely scenario in which no mutually satisfactory agreement can be reached and the UK exits without a deal.</p><p> </p><p>If the clinical trials regulation comes into force during the implementation period, as it is currently expected to do in March 2020, it will apply to the UK. The withdrawal agreement and implementation Bill will give effect to the implementation period in domestic law and will allow regulations to continue to apply in the UK for this time-limited period. If this opportunity does not come to pass, we will give priority to taking the steps necessary to bring into UK law, without delay, all relevant parts of the EU regulation that are within the UK’s control, so that those planning clinical research can do so with certainty.</p><p> </p><p>The UK is already a preferred destination for EU and global clinical trials. The Government has been clear that it is in the interest of patients and the life sciences industry across Europe for the UK and EU to find a way to continue cooperation in the field of clinical trials, and for continued sharing of data and information, even if our precise relationship with the EU will by necessity change. As part of the Department’s Exiting the EU programme, officials are working to ensure appropriate coordination across a number of projects relating to research and clinical trials including workforce, regulations, funding and rare diseases.</p><p> </p><p>The National Institute for Health Research (NIHR) provides the support, expertise and facilities that the National Health Service needs to undertake world-leading clinical trials funded by the NIHR, and other public, charity and life sciences industry partners, by funding a range of infrastructure facilities and the Clinical Research Network. Through NIHR and its partners, and by close collaboration with the life sciences sector and industry, the Government will ensure that the UK remains one of the best places in the world for research, science and innovation.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 26/04/2018 11:21:29 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4036 label Biography information for Luciana Berger

890119

registered interest
date	23/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Clinical Trials: EU Law
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to ensure continued access to the EU clinical trials portal and database after the UK leaves the EU.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	137169
answer	answer is ministerial correction date of answer 26/04/2018 answer text <p>If the Clinical Trials Regulation comes into force during the Implementation Period, as it is currently expected to in March 2020, it will apply to the United Kingdom. The Withdrawal Agreement and Implementation Bill will give effect to the implementation period in domestic law and will allow regulations to continue to apply in the UK for this time-limited period.</p><p> </p><p>If this opportunity does not come to pass, we will give priority to taking the steps necessary to bring into UK law, without delay, all relevant parts of the European Union regulation that are within the UK’s control, so that those planning clinical research can do so with certainty.</p><p> </p><p>The two key elements of the Regulation that are outside of the UK’s control, and this guarantee does not therefore cover, are the use of a shared central IT portal and database and participation in the single assessment model, both of which require a negotiated UK/EU agreement regarding UK involvement post-Brexit. We cannot pre-empt these negotiations, nor can we disadvantage the UK’s position in these negotiations by giving any further guarantees at this time.</p><p> </p><p>Regardless of the outcome of a Brexit deal and the application date of the Regulation, the UK is committed to offering a competitive service for clinical trial assessment. This covers regulatory approval from the Medicines and Health products Regulatory Agency (MHRA) as well as services from the Health Research Authority, ethics services, the National Institute for Health Research and the National Health Service. The current regulatory approval legislation will stay in place until such time as any changes are needed so there will be no interruption in UK clinical trials approval.</p><p> </p><p>In the event that the UK is not part of the EU shared central IT portal and database and therefore trials to be run wholly or in part in the UK are not submitted through the EU portal, it will still be perfectly possible for sponsors to run multistate trials involving the UK. Sponsors would have to apply to the MHRA as well as to the EU concerned states. However, MHRA would take every effort to ensure that a parallel submission to the MHRA was as streamlined and efficient as possible and that we were able to match or better the European timeline for assessment. MHRA and UK ethics committees are already internationally recognised for their robust yet timely assessment of trial applications and the UK is currently one of the most competitive Member States for timelines.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 26/04/2018 11:20:11 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4036 label Biography information for Luciana Berger

890120

registered interest
date	23/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to support the maintenance of links between regulators, research ethics committees, researchers and the pharmaceutical industry in the UK and the European Medicines Agency after the UK leaves the EU.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	137170
answer	answer is ministerial correction date of answer 26/04/2018 answer text <p>The Department has always made clear its intention to retain a close working partnership with the European Union, in the interest of ensuring patients continue to have timely access to safe medicines and medical innovations. This includes maintaining a strong working relationship with the European Medicines Agency on all aspects of the life sciences sector.</p><p> </p><p>It is of mutual benefit for the EU to collaborate closely with such a well-developed life sciences market in the United Kingdom. Both sides will always be stronger by working in partnership.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 26/04/2018 11:23:42 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4036 label Biography information for Luciana Berger

887879

registered interest
date	20/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Motor Vehicles: Disability
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the statutory definition is of a disability access vehicle; and whether that definition is different to a wheelchair accessible vehicle.
tabling member constituency	Cheltenham
tabling member printed	Alex Chalk
uin	136874
answer	answer is ministerial correction date of answer 27/04/2018 answer text <p>The Commission Regulation EU/678/2011, which amends EU Directive 2007/46/EC, defines a wheelchair accessible vehicle as a vehicle of Category M1 constructed or converted specifically so that they accommodate one or more persons seated in their wheelchairs when travelling on the road.</p><p> </p><p>The Road Vehicle (Approval) Regulations 2009, which implement Directive 2007/46/EC in the United Kingdom, define a disabled person’s vehicle as a vehicle constructed or adapted to enable a person with a disability to travel in the vehicle as a driver or a passenger, in safety and reasonable comfort.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 27/04/2018 10:50:13 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4481 label Biography information for Alex Chalk